Regulatory teams are under more pressure than ever to submit clean, review-ready data. SEND has been mandatory for CDER nonclinical studies since 2017. Enforcement of Technical Rejection Criteria has been active since September 2021. By now, you would expect most submissions to be arriving at FDA without structural errors. The data says otherwise. Three years into active TRC enforcement, SEND continues to account for the majority of errors across every rejection code FDA trac

Introduction FDA’s March 2026 release of the Study Data Technical Conformance Guide (TCG v6.2) has been circulating for a few weeks now. For most teams, it reads like a routine update some language refinements, a few new sections, nothing that demands immediate attention. With the addition of Appendix I, that reading is worth revisiting. FDA’s expectations around SEND are shifting from technical compliance toward review readiness. Those are not the same thing, and the gap bet

Introduction As SENDIG v4.0 continues to shape planning discussions for 2026 submissions, many sponsors and CROs are rethinking how they approach SEND readiness. The focus is no longer only on converting data at the end of a study. It is now about building a process that supports clean, traceable, and submission-ready data from the beginning. That shift is important because SEND readiness is not just a technical task. It connects study design, source data quality, mapping dec

Introduction As SEND becomes more established in regulatory submissions to the U.S. FDA, expectations are evolving beyond basic dataset standardization toward greater transparency, expanded domain coverage, and improved support for regulatory review. With SENDIG v4.0 expected to be published in 2026, organizations preparing nonclinical submissions will need to adapt to a broader and more detailed set of requirements. These updates go beyond incremental changes and are likely

Key decision points organizations face when evaluating SEND outsourcing Introduction As SEND continues to play a critical role in U.S. FDA submissions, organizations are increasingly evaluating how best to manage SEND activities across studies. While some teams build internal capabilities, others rely on external partners or adopt a hybrid approach. The right model often depends on factors such as study volume, timelines, internal expertise, and regulatory expectations. In pr

Key stages influencing SEND readiness and where challenges typically arise Introduction With SEND now required for U.S. FDA submissions, its role extends beyond dataset creation and directly influences submission quality, review efficiency, and regulatory confidence. However, achieving SEND readiness is often more complex than anticipated. What appears to be a structured, standards-driven process can become challenging in practice particularly across diverse studies, systems,

Introduction As SEND adoption has matured across regulatory submissions, the focus has gradually shifted beyond technical dataset conversion. Regulatory authorities increasingly evaluate not only whether SEND datasets conform to the standard, but also whether they are transparent, traceable, and suitable for efficient scientific review. Within this evolving environment, validation plays a critical role in ensuring submission quality. While automated validation tools can ident

For Chief Scientific Officers and Regulatory Leaders, SEND is no longer a technical afterthought. It is an operational capability that influences submission readiness, data defensibility, and regulatory confidence across global submissions. As expectations surrounding nonclinical data continue to mature across regions, the question is not simply whether SEND can be delivered — but how SEND dataset preparation and submission support should be structured within the organizatio